SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Mirtazapine Disintegrating Formulation

Manufacturer or supplier’s details
Company: MSD
Address: Rua Treze de Maio, 1161
Campinas, São Paulo, Brazil 13106-054
Telephone: 908-740-4000
Emergency telephone: 55 19 3758 2000
E-mail address: EHSDATASTEWARD@msd.com
Telefax: 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accordance with ABNT NBR 14725 Standard
Acute toxicity (Oral): Category 4
Reproductive toxicity: Category 2
Specific target organ toxicity - repeated exposure (Oral): Category 2 (Nervous system)
Short-term (acute) aquatic hazard: Category 3
Long-term (chronic) aquatic hazard: Category 3

GHS label elements in accordance with ABNT NBR 14725 Standard
Hazard pictograms: 
Signal Word: Warning
Hazard Statements: H302 Harmful if swallowed.
H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.
H373 May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.
Precautionary Statements:

**Prevention:**
- P201 Obtain special instructions before use.
- P260 Do not breathe dust.
- P270 Do not eat, drink or smoke when using this product.
- P273 Avoid release to the environment.
- P280 Wear protective gloves/protective clothing/ eye protection/ face protection.

**Response:**
- P308 + P313 IF exposed or concerned: Get medical advice/attention.

Other hazards which do not result in classification:
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

**Substance / Mixture:** Mixture

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine</td>
<td>85650-52-8</td>
<td>Acute toxicity (Oral), Category 4 Reproductive toxicity, Category 2 Specific target organ toxicity - repeated exposure (Oral) (Nervous system), Category 2 Short-term (acute) aquatic hazard, Category 2 Long-term (chronic) aquatic hazard, Category 2</td>
<td>&gt;= 20 &lt;- 25</td>
</tr>
<tr>
<td></td>
<td>Citric acid</td>
<td>77-92-9</td>
<td>Eye irritation, Category 2A</td>
<td>&gt;= 1 &lt;- 5</td>
</tr>
<tr>
<td></td>
<td>Cellulose</td>
<td>9004-34-6</td>
<td></td>
<td>&gt;= 1 &lt;- 5</td>
</tr>
<tr>
<td></td>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td></td>
<td>&gt;= 1 &lt;- 5</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

**General advice:** In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed: Harmful if swallowed. Suspected of damaging fertility. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during fire fighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)
Metal oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for fire-fighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES
SAFETY DATA SHEET

Mirtazapine Disintegrating Formulation

Version 4.2
Revision Date: 09/13/2019
SDS Number: 50188-00014
Date of last issue: 24.04.2019
Date of first issue: 23.01.2015

Personal precautions, protective equipment and emergency procedures:
Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions:
Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
Use only with adequate ventilation.

Advice on safe handling:
Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

Conditions for safe storage:
Keep in properly labeled containers. Store locked up. Store in accordance with the particular national regulations.

Materials to avoid:
Do not store with the following product types: Strong oxidizing agents.
SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine</td>
<td>85650-52-8</td>
<td>TWA</td>
<td>25 µg/m³</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>250 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>TWA (Inhalable fraction)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Respirable fraction)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

Engineering measures: Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type

Hand protection: Chemical-resistant gloves

Remarks: Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection: Wear the following personal protective equipment: Safety goggles

Skin and body protection: Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc.).
SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder
Color : Not available
Odor : Not available
Odor Threshold : Not available
pH : Not available
Melting point/freezing point : Not available
Initial boiling point and boiling range : Not available
Flash point : Not available
Evaporation rate : Not available
Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids) : Not available
Upper explosion limit / Upper flammability limit : Not available
Lower explosion limit / Lower flammability limit : Not available
Vapor pressure : Not available
Relative vapor density : Not available
Density : Not available
Solubility(ies)
   Water solubility : Not available
Partition coefficient: n-octanol/water : Not available
Autoignition temperature : Not available
Decomposition temperature : Not available
Viscosity
   Viscosity, dynamic : Not available
   Viscosity, kinematic : Not available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Mirtazapine Disintegrating Formulation

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

Conditions to avoid: Heat, flames and sparks. Avoid dust formation.
Incompatible materials: Oxidizing agents

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity:
Harmful if swallowed.

Product:
Acute oral toxicity: Acute toxicity estimate: 1.588 mg/kg
Method: Calculation method

Components:
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Acute oral toxicity: LD50 (Rat): 320 - 490 mg/kg

Citric acid:
Acute oral toxicity: LD50 (Mouse): 5.400 mg/kg
Acute dermal toxicity: LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Cellulose:
Acute oral toxicity: LD50 (Rat): > 5.000 mg/kg
Acute inhalation toxicity: LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Acute dermal toxicity: LD50 (Rabbit): > 2.000 mg/kg

**Magnesium stearate:**
Acute oral toxicity: LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity: LD50 (Rabbit): > 2.000 mg/kg
Remarks: Based on data from similar materials

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

**Citric acid:**
Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation

**Magnesium stearate:**
Species: Rabbit
Result: No skin irritation
Remarks: Based on data from similar materials

**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**

**Citric acid:**
Species: Rabbit
Result: Irritation to eyes, reversing within 21 days
Method: OECD Test Guideline 405

**Magnesium stearate:**
Species: Rabbit
Result: No eye irritation
Remarks: Based on data from similar materials

**Respiratory or skin sensitization**

**Skin sensitization**
Not classified based on available information.

**Respiratory sensitization**
Not classified based on available information.
Components:

Magnesium stearate:
Test Type: Maximization Test
Routes of exposure: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
Result: negative
Remarks: Based on data from similar materials

Germ cell mutagenicity
Not classified based on available information.

Components:

(+/-)-1,2,3,4,10b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative
Test Type: unscheduled DNA synthesis assay
Test system: mammalian cells
Result: negative
Test Type: sister chromatid exchange assay
Test system: mammalian cells
Result: negative

Genotoxicity in vivo: Test Type: Micronucleus test
Species: Rat
Cell type: Bone marrow
Application Route: Oral
Result: negative

Citric acid:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Test Type: In vitro micronucleus test
Result: positive
Test Type: Bacterial reverse mutation assay (AMES) Result: negative

Genotoxicity in vivo: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative
**SAFETY DATA SHEET**

**Mirtazapine Disintegrating Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.2</td>
<td>09/13/2019</td>
<td>50188-00014</td>
<td>24.04.2019</td>
<td>23.01.2015</td>
</tr>
</tbody>
</table>

**Cellulose:**

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  - Result: negative

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Mouse
  - Application Route: Ingestion
  - Result: negative

**Magnesium stearate:**

Genotoxicity in vitro:
- Test Type: In vitro mammalian cell gene mutation test
  - Result: negative
  - Remarks: Based on data from similar materials
- Test Type: Chromosome aberration test in vitro
  - Method: OECD Test Guideline 473
  - Result: negative
  - Remarks: Based on data from similar materials
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
  - Remarks: Based on data from similar materials

**Carcinogenicity**

Not classified based on available information.

**Components:**

**(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:**

- **Species**: Mouse
- **Application Route**: Oral
- **Exposure time**: 18 month(s)
- **LOAEL**: 200 mg/kg body weight
- **Result**: equivocal
- **Target Organs**: Liver

- **Species**: Rat
- **Application Route**: Oral
- **Exposure time**: 2 Years
- **LOAEL**: 20 mg/kg body weight
- **Result**: equivocal
- **Target Organs**: Liver, Thyroid

**Cellulose:**

- **Species**: Rat
- **Application Route**: Ingestion
- **Exposure time**: 72 weeks
- **Result**: negative
Reproductive toxicity
Suspected of damaging fertility. Suspected of damaging the unborn child.

Components:

\((\pm)-1,2,3,4,10,14\text{b}-\text{Hexahydro-2-methylpyrazino}[2,1-a]\text{pyrido}[2,3-c][2]\text{benzazepine}:

Effects on fertility:
- Test Type: Fertility/early embryonic development
- Species: Rat
- Application Route: Oral
- Fertility: LOAEL: 15 mg/kg body weight
- Symptoms: Effect on estrous cycle, Increase of early resorptions.
- Result: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were detected.

Effects on fetal development:
- Test Type: Development
- Species: Rat
- Application Route: Oral
- Developmental Toxicity: LOAEL: 100 mg/kg body weight
- Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

Test Type: Development
- Species: Rabbit
- Application Route: Oral
- Developmental Toxicity: NOAEL: 40 mg/kg body weight
- Result: No adverse effects., No teratogenic effects.

Reproductive toxicity - Assessment:
- Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

Citric acid:

Effects on fetal development:
- Test Type: One-generation reproduction toxicity study
- Species: Rat
- Application Route: Ingestion
- Result: negative

Cellulose:

Effects on fertility:
- Test Type: One-generation reproduction toxicity study
- Species: Rat
- Application Route: Ingestion
- Result: negative

Effects on fetal development:
- Test Type: Fertility/early embryonic development
- Species: Rat
- Application Route: Ingestion
- Result: negative

Magnesium stearate:

Effects on fertility:
- Test Type: Combined repeated dose toxicity study with the
reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on fetal development
Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.

Components:
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Routes of exposure: Ingestion
Target Organs: Nervous system
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Species: Rat
LOAEL: 120 mg/kg
Application Route: Oral
Exposure time: 13 Weeks
Target Organs: Nervous system

Species: Dog
LOAEL: 15 mg/kg
Application Route: Oral
Exposure time: 52 Weeks
Target Organs: Nervous system
Symptoms: Tremors

Species: Dog
LOAEL: 20 mg/kg
Application Route: Oral
Exposure time: 13 Weeks
Target Organs: Nervous system, Testis
Symptoms: Tremors

Citric acid:
SAFETY DATA SHEET

Mirtazapine Disintegrating Formulation

Species: Rat
NOAEL: 4.000 mg/kg
LOAEL: 8.000 mg/kg
Application Route: Ingestion
Exposure time: 10 Days

Cellulose:
Species: Rat
NOAEL: >= 9.000 mg/kg
Application Route: Ingestion
Exposure time: 90 Days

Magnesium stearate:
Species: Rat
NOAEL: > 100 mg/kg
Application Route: Ingestion
Exposure time: 90 Days
Remarks: Based on data from similar materials

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Ingestion: Symptoms: Drowsiness, constipation, dry mouth, asthenia, Dizziness, Disorientation

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): 6.92 mg/l
Exposure time: 96 h
Method: FDA 4.11

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 19.5 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): 5.7 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
NOEC (Pseudokirchneriella subcapitata (green algae)): 3.2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
<table>
<thead>
<tr>
<th>Substance</th>
<th>Toxicity to fish (Chronic toxicity)</th>
<th>Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)</th>
<th>Toxicity to microorganisms</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAFETY DATA SHEET</td>
<td>No toxicity at the limit of solubility.</td>
<td>No toxicity at the limit of solubility.</td>
<td>EC50 (Natural microorganism): &gt; 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 NOEC (Natural microorganism): &lt; 100 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209</td>
<td></td>
</tr>
<tr>
<td>Citric acid</td>
<td>LC50 (Pimephales promelas (fathead minnow)): &gt; 100 mg/l Exposure time: 96 h</td>
<td>EC50 (Daphnia magna (Water flea)): 1.535 mg/l Exposure time: 24 h</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cellulose</td>
<td>LC50 (Oryzias latipes (Japanese medaka)): &gt; 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>LC50 (Leuciscus idus (Golden orfe)): &gt; 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials</td>
<td>EL50 (Daphnia magna (Water flea)): &gt; 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toxicity to algae/aquatic plants</td>
<td>EL50 (Pseudokirchneriella subcapitata (green algae)): &gt; 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility. NOELR (Pseudokirchneriella subcapitata (green algae)): &gt; 1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms:
EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Persistence and degradability

Components:

Citric acid:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 97 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Cellulose:
Biodegradability: Result: Readily biodegradable.

Magnesium stearate:
Biodegradability: Result: Not biodegradable.
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

(+/-)1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Bioaccumulation: Species: Oncorhynchus mykiss (rainbow trout)
Bioconcentration factor (BCF): 334
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water
: log Pow: 2.78

Citric acid:
Partition coefficient: n-octanol/water
: log Pow: -1.72

Magnesium stearate:
Partition coefficient: n-octanol/water
: log Pow: > 4

Mobility in soil

Components:

(+/-)1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Distribution among environ:
: log Koc: 4.48
mental compartments

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations
UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation
ANTT
Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture
National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. Ordinance No. 1274 on the control and monitoring of chemicals. : Sodium hydrogencarbonate

International Regulations
The ingredients of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined
Further information

Full text of other abbreviations
ACGIH: USA. ACGIH Threshold Limit Values (TLV)
ACGIH / TWA: 8-hour, time-weighted average

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.
<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.2</td>
<td>09/13/2019</td>
<td>50188-00014</td>
<td>24.04.2019</td>
<td>23.01.2015</td>
</tr>
</tbody>
</table>

BR / Z8